Abstract Detail

Amir Monfaredan

Tehran University of Medical Sciences, Iran

Abstract

Glioblastoma, also known as glioblastoma multiforme (GBM), is an aggressive type of cancer that can occur in the brain or spinal cord. It arises from astrocytes, the cells that support nerve cells, and is classified as a grade IV astrocytoma due to its highly malignant nature. The median survival time using standard therapy is only 12–15 months with a 5-year survival rate of around 5%. Signal Transducer and Activator of Transcription 3 (STAT3) is a critical transcription factor involved in various cellular processes, including growth, survival, differentiation, and immune response regulation. It is part of the STAT protein family and plays a significant role in mediating the response to various cytokines and growth factors. Here we present data showing that the therapeutic application of siRNAs, formulated in nanoscale liposome (LNP) based on nano lipid (NL) and the exosomes containing STAT3-SiRNA, as a packed molecule represents a promising new approach to target Stat3 in glioma. We show that NLP-Exosome-mediated siRNA delivery mediates the effect of Stat3 in vitro, inhibiting Stat3 activity and limiting cell growth in glioma cells in mice (Tu2449) and humans (U87). This is a primary concept study showing NLP-Exosome complexes are an effective strategy for treating normally drug-resistant oncoproteins.

Audience take away:

The future of glioblastoma therapy isn’t just about finding the right gene target—it’s about delivering it to the right place, at the right time, without collateral damage. The delivery system is the unsung hero."  This ensures your audience leaves with clear, actionable insights while appreciating the interdisciplinary challenge (biology + engineering + medicine). 

Biography

EDUCATION:

  • MSc of modern blood banking and hematology, Tehran medical university, IRAN. 08/2012 to 06/2016.
  • PhD of Molecular Genetic and oncogenetic, Uppsala, medical university, Sweden. 08/2017 to 06/2019.
  • Post Doctorate of Molecular Medicine and Target therapy, Tehran medical university, IRAN. 08/2019 to present.

WORK HISTORY:

  • Molecular genetics researcher, National Hospital, Tabriz, IRAN, 02/2014-08/2017, Supervisor: Dr. Dabiri
  • Medical Manager and QC moderator, National Hospital, Tabriz, IRAN, 02/2014-08/2018, Supervisor:  Dr. Dabiri
  • Genetic Laboratory manager and designer, Noora Genetic Lan, Tehran, IRAN, 02/2018-present, Supervisor:  Dr. Kolaei

TRAINING AND PROFESSIONAL DEVELOPMENT:

  • https://scholar.google.com/citations